^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    m-ceNK cells

    i
    Other names: m-ceNK cells, memory cytokine-enriched natural killer cells
    Associations

    News

    Trials
    Company:
    ImmunityBio
    Drug class:
    NK cell stimulant, IFNγ stimulant
    Related drugs:
    Associations

    News

    Trials
    12d
    Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (clinicaltrials.gov)
    P2, N=0, Withdrawn, ImmunityBio, Inc. | N=20 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    13d
    Immunotherapy Before and After Surgery (clinicaltrials.gov)
    P2, N=0, Withdrawn, ImmunityBio, Inc. | N=20 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    5ms
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    10ms
    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Initiation date: Mar 2025 --> Nov 2024
    Trial initiation date • Platinum resistant
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    1year
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    1year
    Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Jan 2025 --> Jun 2025
    Trial initiation date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    1year
    Immunotherapy Before and After Surgery (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Jan 2025 --> May 2025
    Trial initiation date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Initiation date: Dec 2024 --> Mar 2025
    Trial initiation date
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    Open-Label, Phase 2 Clinical Trial of Pre-Radiation and Post-Radiation Immunotherapy with N 803, ETBX-071, and M-CENK in Combination with Radiation for Participants with High-Risk Prostate Cancer. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    Immunotherapy Before and After Surgery (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial • Combination therapy
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells